Glaucoma: Symptoms, Exam Findings, Treatment & Follow-Up

Glaucoma describes a spectrum of optic neuropathies characterized by progressive loss of retinal ganglion cells and characteristic changes to the optic nerve head and visual field, usually—but not exclusively—in the setting of elevated intraocular pressure (IOP). Chronic primary open-angle glaucoma (POAG) reflects slowed aqueous outflow through the trabecular pathway despite a grossly open angle on gonioscopy. Primary angle-closure disease spans anatomically narrow angles, intermittent spikes of IOP, and acute angle closure where pupillary block abruptly obstructs aqueous passage—producing an IOP surge rapid enough to threaten the optic nerve within hours unless IOP is lowered urgently.

Pathophysiology at the bedside reduces to perfusion and mechanical stress at the lamina cribrosa: sustained IOP elevation (or vascular dysregulation at statistically normal IOP in normal-tension variants) exceeds the optic nerve head tolerance window and drives excavation and arcuate visual field defects that patients rarely notice until substantial peripheral sensitivity is gone. Secondary glaucoma follows steroid responsiveness, pigment dispersion, pseudoexfoliation, trauma, neovascular membranes, or inflammatory trabecular obstruction—each altering monitoring urgency.

For nurses and allied clinicians the operational anchor is longitudinal IOP control paired with structural and functional surveillance—because therapy halts progression rather than reversing damage—and recognizing acute angle-closure presentations that bypass scheduled outpatient timelines.

No universal IOP threshold diagnoses POAG—population distributions skew toward roughly 10–21 mmHg as a screening shorthand, yet nerve tolerance varies individually and normal-tension disease proves IOP alone is insufficient. Targets instead trend downward after confirmation of progression, advanced baseline damage, or thin central corneal thickness influencing measured IOP.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice thresholds follow ophthalmology-led pathways such as NICE NG81—never extrapolate solitary IOP readings taken outside calibrated tonometry workflows into definitive staging.

POAG commonly progresses silently until automated perimetry exposes nasal steps or arcuate defects—patients may complain only of subtle difficulties with stairs or peripheral awareness during driving despite measurable loss.

Typical chronic cues

• Gradual peripheral field constriction misinterpreted as normal ageing.
• Contrast sensitivity complaints before Snellen acuity collapses.
• Monocular occlusion testing reveals unnoticed deficits.

Atypical or masked presentations

• Central preservation early: acuity remains reassuring while fields deteriorate—avoid false reassurance.
• Cataract coupling: lens opacity shifts confuse symptom attribution.
• Secondary mechanisms: steroid-induced IOP rise may lag topical steroid initiation.

Contrast acute closure syndromes where symptoms erupt abruptly—often overnight—with systemic autonomic symptoms prompting mistaken gastroenterology triage unless nurses articulate the painful red-eye cluster.

Aqueous humour production by the ciliary body balances trabecular and uveoscleral outflow; resistance upstream of Schlemm canal dominates POAG pathogenesis whereas pupillary block or plateau iris configurations precipitate angle closure.

Non-modifiable risk clusters

• Age-related trabecular dysfunction and optic nerve susceptibility.
• Black race / Afro-Caribbean ancestry linked with younger onset POAG severity patterns.
• Family history suggesting genetic contribution.
• High hyperopia/narrow anterior chambers predisposing to closure mechanisms.

Modifiable or medically actionable triggers

• Steroid exposure (ocular, inhaled, systemic) prompting IOP surveillance.
• Poor control of vascular contributors discussed alongside glaucoma specialists.
• Diabetes type 2 roughly doubles relative glaucoma risk—align screening cadence.
• Ocular surface adherence barriers causing covert eye-drop omission.

Clinical assessment

• Best-corrected visual acuity contextualizes cataract interference.
• Central corneal thickness adjusts IOP interpretation.
• Gonioscopy distinguishes open-, narrow-, or closed-angle mechanisms.
• Disc examination seeks notch thinning, vertically elongated cupping, RNFL wedge defects.

Functional testing

• Automated white-on-white perimetry tracks progression—baseline reliability matters.
• Repeat scheduling intensifies after therapy changes or unstable IOP.

Structural imaging

• OCT RNFL or ganglion cell analysis assists progression arbitration.
• Compare against normative databases cautiously—segment ethnicity-specific norms where available.

Overlap exists with diabetic retinopathy screening lesions—coordinate referrals so macular therapies do not distract from IOP surveillance.

1. Detection: Risk-stratified comprehensive examination documents IOP, optic nerve appearance, refractive clues to narrow angles.
2. Confirmation: Correlate OCT/RNFL or repeatable field defects before committing lifelong therapy unless IOP catastrophic.
3. Baseline IOP target: Ophthalmology sets individualized IOP targets informed by severity, progression velocity, age, side-effect tolerance.
4. Therapeutic ladder: Begin topical regimen → escalate adjunct agents → consider SLT → incisional surgery/MIGS when visual field progression persists despite tolerated topical IOP lowering.
5. Surveillance rhythm: Earlier visits after drug initiation/titration (often weeks), lengthen intervals once IOP stable without progression.
6. Escalation triggers: New arcuate defects, worsening mean deviation, IOP consistently above individualized goal, adherence breakdown, steroid initiation.

• Optic neuropathy mimics: compressive lesions—urgent imaging when discs appear asymmetric without IOP correlate.
• Prior stroke or stroke mimic: homonymous defects versus nasal steps (stroke pathway when neurological deficits localize centrally).
• Migraine aura: transient positives unlike chronic field loss (migraine patterns).
• Advanced cataract: reversible acuity/contrast decline.
• Hyphema/uveitic IOP spikes: clarify inflammatory debris obstructing trabecular meshwork.

Differentiating gradual vision decline uses symptom tempo plus slit-lamp findings rather than IOP alone.

↔On a small screen, swipe or scroll sideways to see the full table.

Treatment lowers IOP toward individualized targets using topical agents first-line for POAG; acute closure therapies prioritize breaking pupillary block plus pharmacologic IOP collapse.

First-line topical classes

• Prostaglandin analogues: e.g. latanoprost, bimatoprost—often nightly dosing with eyelash pigment monitoring.
• Beta-adrenergic antagonists: timolol—avoid unsupervised use with asthma/bradycardia unless cleared.
• Carbonic anhydrase inhibitors: topical dorzolamide; oral acetazolamide reserved for acute spikes per ophthalmology.
• Alpha-agonists: brimonidine—watch toddlers against central nervous system depression.

Second-line / procedural escalation

• Selective laser trabeculoplasty reduces IOP or adjunct topical burden.
• LPI secures angles anatomically susceptible to closure.
• Filtering surgery or minimally invasive devices when maximal tolerated topical IOP lowering fails progression criteria.

Special populations

• Pregnancy: fetal-risk counselling dictates bespoke topical choices—defer non-essential prostaglandins per maternal–fetal medicine alignment.
• Severe COPD/cardiac block: beta-blocker drops relatively contraindicated.
• Polypharmacy: reconcile systemic absorption despite topical route.

• Document IOP measurement technique consistency (Goldmann versus handheld).
• After starting therapy or laser, revisit IOP within weeks—not months—unless ophthalmology specifies otherwise.
• Treatment failure definition includes reproducible field/OCT worsening despite IOP theoretically “at goal”—prompt regimen reassessment.
• Coordinate pharmacist review when oral beta-blockers coexist with topical timolol.
• Blood pressure measurement contextualizes perfusion-sensitive optic neuropathy debates.
• Teach punctal occlusion when systemic absorption threatens infants or cardiorespiratory-vulnerable adults.

• Irreversible visual field constriction culminating in tunnel vision.
• Central acuity loss in end-stage optic neuropathy.
• Therapy toxicity—conjunctival allergy cycles causing adherence collapse.
• Postoperative hypotony, bleb leaks, endophthalmitis risk after trabeculectomy.
• Steroid-response IOP spikes progressing unnoticed without screening.

Population prevention hinges on detecting asymptomatic IOP elevation and optic neuropathy early—risk-stratified dilated examinations outperform symptom vigilance alone.

• Flag steroid-containing prescriptions across specialties for IOP surveillance timing.
• Reinforce genetic clustering—first-degree relatives merit earlier baseline examinations.
• Align systemic vascular optimization without implying casual IOP normalization replaces drops.

With sustained IOP lowering and reliable surveillance many patients retain functional independence decades; prognosis worsens when adherence gaps coincide with aggressive papillary excavation or delayed acute closure treatment.

• Use teach-back after demonstrating drop instillation angles—many patients touch bottles to ocular surfaces inadvertently.
• Colour-code bottles when dexterity declines—avoid relying on identical caps alone.
• Interpreter services must capture nuanced adherence barriers.
• Document driving occupation explicitly—refer licensing conversations to ophthalmology letters.

• IOP trend: note measurement modality + time vs topical dosing schedule.
• Surface tolerance: hyperemia, itching, tearing suggesting preservative intolerance.
• Systemic beta-blocker clue: bradycardia or bronchospasm after drop regimen expansion.
• Steroid chronology: reconcile perioperative packs or dermatology creams.
• Vision symptom screen: new central blur (loss of vision pathway triggers).

• Severe painful red eye + nausea ± IOP-induced corneal clouding.
• Sudden monocular vision extinguishment pending vascular or acute closure differentiation.
• Postoperative nausea with shallow anterior chamber pain after trabeculectomy.
• Chemical splash or penetrating trauma altering IOP dynamics.

Symptom triggers

• Rapid enlarging blind spots despite nightly prostaglandin adherence.
• Frequent topical shortages suggesting logistical—not intentional—non-adherence.
• New aura-negative thunderclap headache coupling ocular signs.

Objective escalation cues

• IOP trending ≥ individualized goal across consecutive visits.
• OCT RNFL thinning velocities accelerating versus baseline noise.
• Mean deviation deterioration exceeding expected test–retest variability.

Escalate same-day to ophthalmology urgent clinic when acute closure suspected; arrange accelerated elective review when chronic progression signatures emerge between scheduled intervals.

Pre-treatment education

• Explain lifelong cadence—drops preserve remaining nerves rather than restoring sight.
• Pair demonstrations with written diagrams referencing eye care hygiene principles.

During therapy monitoring

• Capture adverse reactions prompting preservative-free switches.
• Verify inhaler/nebulized steroid overlaps needing IOP surveillance reminders.

Post-laser / surgical phases

• Shield instructions, steroid-antibiotic drop timing, positional restrictions per ophthalmology orders.
• Pain escalation thresholds prompting telephone triage lines.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of acute angle-closure red flags, topical beta-blocker systemic absorption (punctal occlusion), OCT/visual-field progression and IOP adherence—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action.